Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. Utilizing its proprietary platform, the company enhances the immune system's capacity to identify and eliminate tumor cells, thereby improving therapeutic efficacy and patient outcomes. With a robust pipeline of clinical candidates aimed at addressing critical unmet needs in oncology, Indaptus is strategically positioned for growth in a competitive market. By fostering collaborations with leading research institutions and a commitment to scientific innovation, Indaptus aspires to emerge as a key player in the biopharmaceutical sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$1.22
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 13, 2026 | $-1.57 | $-0.02 | Beat +98.7% | $-0.02 | $0 | $0 | — | 1D Pre-14.3% | On-Day+3.9% | 1D Post+0.9% |
Q ended Mar 31, 2026 Report date n/a | $-1.87 | — | — | $-0.23 | $0 | $0 | — | 1D Pre— | On-Day— | 1D Post— |
Q ended Dec 31, 2025 Reported Mar 17, 2026 | $-4.36 | $-9.19 | Miss -110.8% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre-1.1% |
| On-Day+12.0% |
| 1D Post-4.6% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.20 | $-2.98 | Miss -1390.0% | — | $0 | $0 | — | 1D Pre+8.4% | On-Day+6.2% | 1D Post+2.4% |